Literature DB >> 27068342

Prevalence and characteristics of lymphoedema at a wound-care clinic.

W Wang1, D H Keast2.   

Abstract

OBJECTIVE: Lymphoedema is estimated to affect up to 300,000 Canadians but remains underrecognised and undertreated. A retrospective chart review was conducted to determine the clinical characteristics and treatment practices of lymphoedema in a Canadian wound care clinic.
METHOD: Data were collected retrospectively from dictated clinic notes of 326 lymphoedema patients at a wound clinic in a regional rehabilitation hospital.
RESULTS: The mean age (±SD) of diagnosis was 66.8 (±15.5). Patients had 7.3 (±3.3) comorbidities and took 8.4 (±4.6) concomitant medications. The most common comorbidities were venous disease (73%), hypertension (60%), and obesity (46%). Clinic patients were less likely to be women, have arm lymphoedema, or have cancer-related aetiology compared with previous studies, reflecting a two-tiered model of care delivery in the area. Treatments prescribed by the clinic were consistent best practice recommendations for conservative treatment.
CONCLUSION: A significant proportion of the wound clinic's patients had lymphoedema. Lack of resources, lack of awareness among primary care providers, and patient adherence are barriers to lymphoedema care.

Entities:  

Keywords:  complex oedema; obesity; retrospective chart review; secondary lymphoedema; venous disease

Mesh:

Year:  2016        PMID: 27068342     DOI: 10.12968/jowc.2016.25.Sup4.S11

Source DB:  PubMed          Journal:  J Wound Care        ISSN: 0969-0700            Impact factor:   2.072


  2 in total

1.  Worldwide assessment of healthcare personnel dealing with lymphoedema.

Authors:  Henrike Schulze; Marisa Nacke; Christoph Gutenbrunner; Catarina Hadamitzky
Journal:  Health Econ Rev       Date:  2018-04-16

2.  Lymphedema Impact and Prevalence International Study: The Canadian Data.

Authors:  David H Keast; Christine Moffatt; Ashrafunissa Janmohammad
Journal:  Lymphat Res Biol       Date:  2019-04       Impact factor: 2.589

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.